ARWR
Arrowhead Pharmaceuticals Inc.

12,371
Mkt Cap
$9.52B
Volume
5.00
52W High
$72.36
52W Low
$9.57
PE Ratio
-1,018.60
ARWR Fundamentals
Price
$68.45
Prev Close
$70.09
Open
$69.51
50D MA
$45.69
Beta
1.58
Avg. Volume
2.52M
EPS (Annual)
-$0.0122
P/B
19.93
Rev/Employee
$1.17M
Loading...
Loading...
News
all
press releases
36,469 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Marex Group plc
Marex Group plc acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and...
MarketBeat·23h ago
News Placeholder
More News
News Placeholder
WINTON GROUP Ltd Invests $660,000 in Arrowhead Pharmaceuticals, Inc. $ARWR
WINTON GROUP Ltd purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·4d ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
Royal Bank Of Canada raised their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an "outperform" rating in a research report on Thursday...
MarketBeat·5d ago
News Placeholder
Michael Perry Sells 16,250 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) Director Michael Perry sold 16,250 shares of the company's stock in a transaction on Friday, December 5th. The stock was sold at an...
MarketBeat·6d ago
News Placeholder
Bank of America Issues Positive Forecast for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price
Bank of America upped their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a "buy" rating in a research report on Tuesday...
MarketBeat·7d ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down - Time to Sell?
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down - Should You Sell...
MarketBeat·7d ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year High - Time to Buy?
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 12-Month High - Time to Buy...
MarketBeat·8d ago
News Placeholder
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimers Disease and Other Tauopathies
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the companys investigational RNA interference (RNAi...
Business Wire·8d ago
News Placeholder
Marshall Wace LLP Grows Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR
Marshall Wace LLP increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 3,507.8% in the second quarter, according to the company in its most recent 13F filing with the...
MarketBeat·8d ago
News Placeholder
Norges Bank Invests $30.41 Million in Arrowhead Pharmaceuticals, Inc. $ARWR
Norges Bank acquired a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·8d ago
<
1
2
...
>

Latest ARWR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.